Description
Irsogladine is a gastroprotective agent. It increases transfer of Lucifer yellow CH between isolated rabbit gastric epithelial cells, indicating enhanced gap junction intercellular communication (GJIC). Irsogladine (3 mg/kg) inhibits gastric mucosal lesion formation and decreases in gastric mucosal blood flow induced by monochloramine in rats, effects that can be prevented by the nitric oxide synthase inhibitor L-NAME . It also inhibits superoxide anion production induced by fMLP and increases cAMP levels in isolated human neutrophils in a concentration-dependent manner, similar to the phosphodiesterase 4 (PDE4) inhibitor rolipram .
Chemical Properties
White Solid
Uses
An anti-ulcer drug. Potent PDE4 inhibitor
Uses
antiulcerative;selective PDE4 inhibitor which also enhances gap junction intercellular communication
Definition
ChEBI: Irsogladine maleate is a dichlorobenzene.
Biological Activity
Phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties. Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Activates gap-junctional intercellular communication improving gastric mucosal barrier function. Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis.
References
[1] TAKASHI KYOI. Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.[J]. Journal of pharmacological sciences, 2003, 93 3: 314-320. DOI:
10.1254/jphs.93.314[2] F UEDA T I K Ban. Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor.[J]. Journal of Pharmacology and Experimental Therapeutics, 1995, 274 2: 815-819.
[3] TAKASHI KYOI. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils[J]. Life sciences, 2004, 76 1: Pages 71-83. DOI:
10.1016/j.lfs.2004.06.016
